IL309177A - Nitroxoline for use in the treatment of cutaneous neurofibroma - Google Patents
Nitroxoline for use in the treatment of cutaneous neurofibromaInfo
- Publication number
- IL309177A IL309177A IL309177A IL30917723A IL309177A IL 309177 A IL309177 A IL 309177A IL 309177 A IL309177 A IL 309177A IL 30917723 A IL30917723 A IL 30917723A IL 309177 A IL309177 A IL 309177A
- Authority
- IL
- Israel
- Prior art keywords
- nitroxoline
- treatment
- cutaneous neurofibroma
- neurofibroma
- cutaneous
- Prior art date
Links
- 201000004404 Neurofibroma Diseases 0.000 title 1
- RJIWZDNTCBHXAL-UHFFFAOYSA-N nitroxoline Chemical compound C1=CN=C2C(O)=CC=C([N+]([O-])=O)C2=C1 RJIWZDNTCBHXAL-UHFFFAOYSA-N 0.000 title 1
- 229960005131 nitroxoline Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2108224.3A GB202108224D0 (en) | 2021-06-09 | 2021-06-09 | Treatment |
| PCT/GB2022/051442 WO2022258972A1 (en) | 2021-06-09 | 2022-06-09 | Nitroxoline for use in the treatment of cutaneous neurofibroma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL309177A true IL309177A (en) | 2024-02-01 |
Family
ID=76838879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL309177A IL309177A (en) | 2021-06-09 | 2022-06-09 | Nitroxoline for use in the treatment of cutaneous neurofibroma |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240261276A1 (enExample) |
| EP (1) | EP4351576A1 (enExample) |
| JP (1) | JP2024520690A (enExample) |
| KR (1) | KR20240024175A (enExample) |
| CN (1) | CN117769419A (enExample) |
| AU (1) | AU2022290019A1 (enExample) |
| BR (1) | BR112023025789A2 (enExample) |
| CA (1) | CA3221964A1 (enExample) |
| GB (1) | GB202108224D0 (enExample) |
| IL (1) | IL309177A (enExample) |
| MX (1) | MX2023014530A (enExample) |
| WO (1) | WO2022258972A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202116743D0 (en) * | 2021-11-19 | 2022-01-05 | Healx Ltd | Treatment |
| GB202218460D0 (en) * | 2022-12-08 | 2023-01-25 | Healx Ltd | Treatment |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2970128B1 (en) * | 2013-03-15 | 2019-12-04 | Asieris Pharmaceutical Technologies Co., Ltd. | Base addition salts of nitroxoline and uses thereof |
| CA3287905A1 (en) * | 2016-10-14 | 2025-11-29 | Wake Forest University Health Sciences | Compositions, cell constructs, and methods of making and using the same |
| EP3883552B1 (en) * | 2018-11-20 | 2025-04-09 | NFlection Therapeutics, Inc. | Cyanoaryl-aniline compounds for treatment of dermal disorders |
| CN112402388A (zh) * | 2019-08-05 | 2021-02-26 | 江苏亚虹医药科技股份有限公司 | 一种用于治疗膀胱癌的口服固体制剂及其制备方法 |
-
2021
- 2021-06-09 GB GBGB2108224.3A patent/GB202108224D0/en not_active Ceased
-
2022
- 2022-06-09 KR KR1020247000745A patent/KR20240024175A/ko active Pending
- 2022-06-09 MX MX2023014530A patent/MX2023014530A/es unknown
- 2022-06-09 CA CA3221964A patent/CA3221964A1/en active Pending
- 2022-06-09 US US18/567,829 patent/US20240261276A1/en active Pending
- 2022-06-09 WO PCT/GB2022/051442 patent/WO2022258972A1/en not_active Ceased
- 2022-06-09 EP EP22732622.0A patent/EP4351576A1/en active Pending
- 2022-06-09 CN CN202280040639.5A patent/CN117769419A/zh active Pending
- 2022-06-09 IL IL309177A patent/IL309177A/en unknown
- 2022-06-09 JP JP2023574531A patent/JP2024520690A/ja active Pending
- 2022-06-09 BR BR112023025789A patent/BR112023025789A2/pt unknown
- 2022-06-09 AU AU2022290019A patent/AU2022290019A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023014530A (es) | 2024-04-10 |
| US20240261276A1 (en) | 2024-08-08 |
| JP2024520690A (ja) | 2024-05-24 |
| BR112023025789A2 (pt) | 2024-02-27 |
| CA3221964A1 (en) | 2022-12-15 |
| WO2022258972A1 (en) | 2022-12-15 |
| CN117769419A (zh) | 2024-03-26 |
| EP4351576A1 (en) | 2024-04-17 |
| AU2022290019A1 (en) | 2023-12-14 |
| KR20240024175A (ko) | 2024-02-23 |
| GB202108224D0 (en) | 2021-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021551455A1 (en) | Jak1 pathway inhibitors for the treatment of gastrointestinal disease | |
| ZA202103977B (en) | Compounds and their use for the treatment of alpha1-antitrypsin deficiency | |
| ZA202307970B (en) | Compounds for use in the treatment and prevention of covid- 19 | |
| IL309576A (en) | History of arylcyclohexylamine and their use in the treatment of psychiatric disorders | |
| IL288924A (en) | Casein kinase 1 inhibitors for use in the treatment of diseases associated with the expression of dux4 such as muscular dystrophy and cancer | |
| LT4340842T (lt) | Sotorasibas, skirtas naudoti vėžio gydymui | |
| PL3846788T3 (pl) | Inhibitory pde11 do zastosowania w leczeniu choroby parkinsona | |
| IL312885A (en) | Nitroxoline for use in the treatment or prevention of flexiform neurofibroma | |
| ZA201903828B (en) | Novel glutaminyl cyclase inhibitors and the use thereof in treatment of various diseases | |
| ZA202006886B (en) | R-fadrozole for use in the treatment of aldostonerism | |
| GB201918404D0 (en) | Compounds and their use for the treatment of aplha1-antitrypsin deficiency | |
| IL309172A (en) | Vulbanazine for use in the additional treatment of schizophrenia | |
| MX2023014530A (es) | Nitroxolina para su uso en el tratamiento de neurofibroma cutaneo. | |
| IL276697A (en) | 3 Beta-(4-methoxybenzyloxy)paragan-5-en-20-one for use in the treatment of cannabinoid-related disorders | |
| HK40110396A (en) | Nitroxoline for use in the treatment of cutaneous neurofibroma | |
| PL3897655T3 (pl) | 3beta-(benzyloksy)-17alfa-metylo-pregn-5-en-20-on do stosowania w leczeniu zaburzeń poznawczych | |
| PL4146225T3 (pl) | Związki metylotioniniowe do zastosowania w leczeniu hipoksemii | |
| IL276228A (en) | Compounds and preparations for the treatment of pain | |
| PT3589632T (pt) | Novos inibidores de glutaminil ciclases bacterianas para utilização no tratamento de doenças periodontais e relacionadas | |
| IL327100A (en) | Alsonarsen/PRAX-22 for use in the treatment of SCN2A-related disorders | |
| HK40088920A (en) | Methylthioninium compounds for use in the treatment of covid-19 | |
| HK40087864A (en) | Methylthioninium compounds for use in the treatment of covid-19 | |
| HK40117088A (en) | Nitroxoline for use in the treatment or prevention of a plexiform neurofibroma | |
| IL310580A (en) | RALOXIFENE for use in the treatment of SARS-COV-2 infections | |
| ZA202208468B (en) | Use of ketamine in the treatment of cachexia |